“Long-acting dual agonist of exendin-4 and FGF21 promises improved treatment for type 2 diabetes mellitus and obesity”

https://pubmed.ncbi.nlm.nih.gov/38116563

A long-acting dual agonist of exendin-4 and FGF21 shows promise for treating type 2 diabetes mellitus and obesity due to its prolonged half-life and enhanced blood glucose lowering bioactivity.